Figure 3.

Kaplan–Meier curves for EGFR mutant non-small cell lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors. (A) PFS between high and low baseline lymphocyte-to-monocyte ratio (LMR) patients; (B) PFS between high and low neutrophil-to-lymphocyte ratio (NLR) patients; (C) OS between high and low baseline LMR patients; (D) OS between high and low baseline NLR patients. LMR = lymphocyte-to-monocyte ratio, NLR = neutrophil-to-lymphocyte, OS = overall survival, PFS = progression-free survival.